Healthcare / Medical DevicesNasdaqGS
$4.54
-0.32 (-6.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.9M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$247M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.1%
↓Gross Margin
86.2%
↑Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+22.9%
FCF CAGR
—
FCF margin
-38.7%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $77.4M · net income $-38.4M · FCF $-29.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $77.4M | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M | $27.6M |
| Net Income | $-38.4M | $-38.4M | $-51.5M | $-55.5M | $-86.2M | $-63.0M | $-34.7M |
| EBITDA | $-32.8M | $-32.8M | $-45.9M | $-49.4M | $-81.0M | — | — |
| EPS | — | — | -1.03 | -1.14 | -1.80 | -2.36 | — |
| Gross Margin | 86.2% | 86.2% | 85.5% | 85.3% | 82.7% | 82.4% | 66.7% |
| Operating Margin | -48.0% | -48.0% | -63.3% | -70.7% | -117.7% | -105.2% | -116.5% |
| Net Margin | -49.7% | -49.7% | -64.5% | -68.5% | -120.9% | -128.6% | -125.5% |
| Balance Sheet | |||||||
| Debt/Equity | 0.64 | 0.64 | 0.46 | 0.29 | 0.22 | 0.14 | -0.36 |
| Current Ratio | 5.86 | 5.86 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-29.9M | $-29.9M | $-22.7M | $-48.0M | $-76.9M | $-53.4M | $-33.1M |
| Returns | |||||||
| ROE | -60.1% | -60.1% | -58.8% | -46.2% | -53.9% | -27.1% | 39.0% |
| Valuation | |||||||
| P/B | 3.80 | 3.80 | 2.00 | 2.08 | 3.99 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -3.1% | -3.1% | -1.5% | 13.6% | — | 77.1% | — |
| EPS Growth | — | — | 9.6% | 36.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.03 → n/d
Residual
+23.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.